A nice recognition. Created in 2019, the Grand Prix Oberling-Haguenau Each year distinguishes a researcher and his team having brought major advances in understanding or taking care of cancers.
Since 2023, it has been completed by the thesis prize which rewards a young doctor of oncology for the quality and originality of his thesis work. April 15, two Toulouse were thus rewarded.
Hervé Avet-Loiseau, specialist in multiple myeloma
Responsible for the “Génomique du Myelome” unit at the CRCT and the CHU in Toulouse since 2012, Professor Hervé Avet-Loiseau is one of the great world specialists in multiple myelome, second cancer Bone marrow in France.
His team notably highlighted Several key genetic anomalies influencing the prognosis of patients, as well as the presence of detectable cell heterogeneity from the diagnosis.
His research today makes it possible to optimize immunotherapy By identifying the patients most likely to respond, while opening the way for new therapeutic approaches for other patient profiles.
Among the three winners awarded this year, Professor Hervé Avet-Loiseau is awarded the Oberling-Haguenau Grand Prix, with 150,000 euroswho comes to salute the excellence and the international impact of his research carried out from Toulouse.
Léa Montégut, awarded for her work on antitumoral immunity
After first studies in Toulouse then in Montreal (INP), Léa Montégut continues her scientific journey in the United States where she is doing a research course at Columbia University in New York.
She then leads her thesis in the Laboratory “Metabolism, cancer and immunity” Directed by Professor Guido Kroemer, at the Cordeliers Research Center (CRC) in Paris and Gustave-Roussy.
His work, published in 2024 in the journal Molecular Cancerhighlighted the role of a metabolic protein in the development and treatment of cancer. In particular, it has shown that its neutralization improves the effectiveness of treatments.
Since last January, Léa Montégut continues her research in post-doctorate at Icahn School of Medicine at Mount Sinai (New York)where she is interested in the links between the aging of the myeloid compartment and the development of cancers.
>> Read also: Toulouse oncopole launches a decentralized clinical trial platform
